TP53 and pancreatic adenocarcinoma: Another finding is that TP53 mutations have a significant effect on the promoter methylation levels of most members of the PHLDA family, and PHLDA1/3 may be potential downstream targets to drive the occurrence and development of PAAD with TP53 mutations.